Clinical Trials Logo

Urolithiasis clinical trials

View clinical trials related to Urolithiasis.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04153461 Active, not recruiting - Urolithiasis Clinical Trials

Mini- Percutaneous Nephrolithotomy Versus Standard Percutaneous Nephrolithotomy in the Treatment of Renal Stones.

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The EUA Urolithiasis Guidelines Panel meta-analysis suggest that mPNL is at least as efficacious and safe as sPNL for the removal of renal calculi. However, the quality of the evidence was poor, drawn mainly from small studies, the majority of which were single-arm case series, and only one of which was RCT. The risks of bias and confounding were high, highlighting the need for more reliable data from RCTs. So, the Panel recommended for more clinical research . The aim of this study is to compare between PNL and mPNL through a randomized controlled trial.

NCT ID: NCT03811171 Active, not recruiting - Renal Calculi Clinical Trials

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

Start date: August 20, 2019
Phase: N/A
Study type: Interventional

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.

NCT ID: NCT03752684 Active, not recruiting - Clinical trials for Calcium Oxalate Urolithiasis

Oxalobacter Formigenes Colonization and Urinary Oxalate Excretion

Start date: April 2, 2018
Phase: N/A
Study type: Interventional

The purpose of this research study is to assess the efficacy of ingesting a small amount of the harmless bacterium Oxalobacter formigenes in establishing residence in the guts of human subjects and to determine whether this influences the oxalate passed in urine of healthy volunteers.

NCT ID: NCT02519153 Active, not recruiting - Urolithiasis Clinical Trials

Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones

Start date: July 2014
Phase: Phase 4
Study type: Interventional

Urolithiasis is one of the most common urological diseases. The risk of urolithiasis is estimated to be between 5% and 12% all over the world with increased incidence in male rather than female (2:1) respectively . Ureteral stones account for 20% from all urinary tract stones, more than 70% of the ureteral stones found in the lower third of the ureter . The incidence of urinary stones has been increasing day by day. Medical expulsive therapy (MET) of ureteral stones is the investigators' concern in this study. Stone location, size, number, ureteral spasm, mucosal edema or inflammation and ureteral anatomy are the factors affecting passage of the ureteral stones. So, MET is based on mechanism that stone passage is facilitated by the relaxation of ureteral smooth muscle , increasing hydrostatic pressure proximal to the stone and decreasing exciting edema . There are many oral medication could be used as MET such as adrenergic blockers, calcium channel blockers, prostaglandin synthesis inhibitors, glyceryl trinitrate and steroid treatment . Calcium-channel blockers and adrenergic α-antagonists are the main that has been proposed to enhance stone passage as expulsive medical therapy. Cyclic nucleotides are degraded by phosphodiesterases enzymes (PDEs). So using of PDE inhibtors may play role in relaxation of smooth muscle of the ureter. A study was done for evaluation of three PDE5 inhibtors, sildenafil , vardenafil and tadalafil, they found that PDE5 inhibitors can reverse the tension of isolated human ureteral smooth muscle via cGMP-mediated pathways.

NCT ID: NCT02028559 Active, not recruiting - Urolithiasis Clinical Trials

Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

Start date: January 2014
Phase: N/A
Study type: Interventional

This study tests moving kidney stones using focused ultrasound (referred to as ultrasonic propulsion). The study includes multiple population groups to investigate the ability of our technology to: a) move stone fragments to a location within the kidney to improve their chances of passage, and thus reduce the occurrence of additional symptomatic events and retreatment or b) move a symptomatic stone to relieve symptoms and pain.

NCT ID: NCT01235104 Active, not recruiting - Urolithiasis Clinical Trials

Impact of Total Nephrectomy on Patients With Kidney Stone

Start date: January 2001
Phase: N/A
Study type: Observational

The aim of this study is to investigate the outcomes of total nephrectomy on patients with kidney stone disease.

NCT ID: NCT00575432 Active, not recruiting - Clinical trials for Kidney Transplantation

Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy

Start date: November 2004
Phase:
Study type: Observational

Multimodal functional magnetic resonance (MR) methods, including MR diffusion, Blood-Oxygenation Level Dependent (BOLD) imaging and MR spectroscopy may provide complementary information about the functional status of a kidney. The researchers hypothesize that these non-invasive methods correlate with histology as "gold standard" and compete favorably with conventional in part invasive evaluation methods, and thus provide specific and early detection of kidney diseases of various etiologies, drug toxicity, or renal allograft dysfunction.